Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Live Hexavalent Reassortant Rotavirus Vaccine in Chinese Infants
ChiCTR2100054584Phase 3Recruiting
- Sponsor
- Hebei Provincial Center for Disease Control and Prevention
- Start
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hexavalent reassortant rotavirus live vaccine in gastroenteritis (2 arms), sponsored by Hebei Provincial Center for Disease Control and Prevention. Primary endpoint: Protective effect against rotavirus diarrhea. Started Mar 2019; status: recruiting.
02
Drugs
hexavalent reassortant rotavirus live vaccine
03
Conditions
gastroenteritis
Beyond the preview
Go deeper on ChiCTR2100054584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054584.